These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 24065118

  • 21. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
    Huang P, Watanabe M, Kaku H, Kashiwakura Y, Chen J, Saika T, Nasu Y, Fujiwara T, Urata Y, Kumon H.
    Cancer Gene Ther; 2008 May; 15(5):315-22. PubMed ID: 18274558
    [Abstract] [Full Text] [Related]

  • 22. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.
    Fang L, Cheng Q, Li W, Liu J, Li L, Xu K, Zheng J.
    Virus Res; 2014 Mar 06; 181():61-71. PubMed ID: 24463503
    [Abstract] [Full Text] [Related]

  • 23. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
    Liu L, Wu W, Zhu G, Liu L, Guan G, Li X, Jin N, Chi B.
    Int J Mol Med; 2012 Oct 06; 30(4):747-54. PubMed ID: 22842823
    [Abstract] [Full Text] [Related]

  • 24. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
    Zhang J, Wei F, Wang H, Li H, Qiu W, Ren P, Chen X, Huang Q.
    Cancer Biother Radiopharm; 2010 Aug 06; 25(4):487-95. PubMed ID: 20735209
    [Abstract] [Full Text] [Related]

  • 25. The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment.
    Hashimoto Y, Tazawa H, Teraishi F, Kojima T, Watanabe Y, Uno F, Yano S, Urata Y, Kagawa S, Fujiwara T.
    PLoS One; 2012 Aug 06; 7(6):e39292. PubMed ID: 22720091
    [Abstract] [Full Text] [Related]

  • 26. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.
    Cancer Gene Ther; 2004 Mar 06; 11(3):174-85. PubMed ID: 14726958
    [Abstract] [Full Text] [Related]

  • 27. Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.
    Tazawa H, Hasei J, Yano S, Kagawa S, Ozaki T, Fujiwara T.
    Cancers (Basel); 2020 Feb 18; 12(2):. PubMed ID: 32085583
    [Abstract] [Full Text] [Related]

  • 28. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
    Dong F, Wang L, Davis JJ, Hu W, Zhang L, Guo W, Teraishi F, Ji L, Fang B.
    Clin Cancer Res; 2006 Sep 01; 12(17):5224-30. PubMed ID: 16951242
    [Abstract] [Full Text] [Related]

  • 29. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.
    Fujiwara T, Shirakawa Y, Kagawa S.
    Expert Rev Anticancer Ther; 2011 Apr 01; 11(4):525-32. PubMed ID: 21504319
    [Abstract] [Full Text] [Related]

  • 30. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.
    Kishimoto H, Urata Y, Tanaka N, Fujiwara T, Hoffman RM.
    Mol Cancer Ther; 2009 Nov 01; 8(11):3001-8. PubMed ID: 19887549
    [Abstract] [Full Text] [Related]

  • 31. Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.
    Li G, Kawashima H, Ogose A, Ariizumi T, Xu Y, Hotta T, Urata Y, Fujiwara T, Endo N.
    J Cancer Res Clin Oncol; 2011 Jun 01; 137(6):1037-51. PubMed ID: 21193997
    [Abstract] [Full Text] [Related]

  • 32. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T, Urata Y, Tanaka N.
    Curr Cancer Drug Targets; 2007 Mar 01; 7(2):191-201. PubMed ID: 17346111
    [Abstract] [Full Text] [Related]

  • 33. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N, Kuroda S, Kakiuchi Y, Kumon K, Tsumura T, Hashimoto M, Morihiro T, Kubota T, Aoyama K, Kikuchi S, Nishizaki M, Kagawa S, Tazawa H, Mizuguchi H, Urata Y, Fujiwara T.
    Mol Ther; 2020 Mar 04; 28(3):794-804. PubMed ID: 31991110
    [Abstract] [Full Text] [Related]

  • 34. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.
    Cancer Gene Ther; 2008 Mar 04; 15(3):173-82. PubMed ID: 18157145
    [Abstract] [Full Text] [Related]

  • 35. Telomerase-specific replication-selective virotherapy for human cancer.
    Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N, Fujiwara T.
    Clin Cancer Res; 2004 Jan 01; 10(1 Pt 1):285-92. PubMed ID: 14734481
    [Abstract] [Full Text] [Related]

  • 36. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
    Sakakibara A, Tsukuda M, Kondo N, Ishiguro Y, Kimura M, Fujita K, Takahashi H, Matsuda H.
    Auris Nasus Larynx; 2011 Oct 01; 38(5):589-99. PubMed ID: 21362583
    [Abstract] [Full Text] [Related]

  • 37. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
    Yano S, Tazawa H, Kishimoto H, Kagawa S, Fujiwara T, Hoffman RM.
    Int J Mol Sci; 2021 Jan 17; 22(2):. PubMed ID: 33477279
    [Abstract] [Full Text] [Related]

  • 38. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
    Xie M, Niu JH, Chang Y, Qian QJ, Wu HP, Li LF, Zhang Y, Li JL, Huang XJ, Ruan GR.
    Apoptosis; 2009 Sep 17; 14(9):1086-94. PubMed ID: 19551515
    [Abstract] [Full Text] [Related]

  • 39. Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus.
    Uotani K, Tazawa H, Hasei J, Fujiwara T, Yoshida A, Yamakawa Y, Omori T, Sugiu K, Komatsubara T, Kondo H, Morita T, Kiyono M, Yokoo S, Hata T, Kunisada T, Takeda K, Urata Y, Fujiwara T, Ozaki T.
    PLoS One; 2024 Sep 17; 19(2):e0298292. PubMed ID: 38377118
    [Abstract] [Full Text] [Related]

  • 40. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
    Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, Onimatsu H, Urata Y, Fujiwara T.
    Mol Cancer Ther; 2009 Apr 17; 8(4):980-7. PubMed ID: 19372571
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.